Skip to content

SONNET BIOTHERAPEUTICS HOLDINGS, INC.: financial reference

Explore SONNET BIOTHERAPEUTICS HOLDINGS, INC. financial histories from SEC filings, with original units, reporting periods, filing dates and downloadable source data.

Reported financial histories

Choose a measure to inspect its definition, complete selected history and filing provenance. Each row shows the latest period available for that selected concept and original unit. Separate currencies and reporting intervals remain separate rows. Coverage dates can differ between concepts. A recent capture does not imply recent accounting coverage; these amounts are not prices.

Latest periods by selected concept and original unit
MeasurePeriod startPeriod endValueUnitFiled
Total assetsAt date2025-09-3014,884,558USD2025-12-16
Total liabilitiesAt date2025-09-304,096,979USD2025-12-16
Stockholders equityAt date2025-09-3010,787,579USD2025-12-16
Cash and cash equivalentsAt date2025-09-305,120,264USD2025-12-16
Net income or loss2024-10-012025-09-30-16,011,487USD2025-12-16
Operating cash flow2024-10-012025-09-30-12,827,199USD2025-12-16
Capital expenditure payments2020-10-012021-09-303,623USD2022-12-15
Revenue2018-01-012018-12-3140,613,709USD2019-04-01
Contract revenue excluding tax2024-10-012025-09-301,000,000USD2025-12-16
Financing cash flow2024-10-012025-09-3026,047,009USD2025-12-16
Investing cash flow2024-10-012025-09-30-12,000USD2025-12-16
Retained earnings or deficitAt date2025-09-30-133,692,472USD2025-12-16
Basic weighted-average shares2024-10-012025-09-304,081,296shares2025-12-16
Diluted weighted-average shares2024-10-012025-09-304,081,296shares2025-12-16
Basic earnings per share2024-10-012025-09-30-3.95USD/shares2025-12-16
Diluted earnings per share2024-10-012025-09-30-3.95USD/shares2025-12-16
Income tax expense or benefit2024-10-012025-09-30218,400USD2025-12-16
Net property, plant and equipmentAt date2025-09-3010,906USD2025-12-16
Share-based compensation expense2024-10-012025-09-30199,595USD2025-12-16
Operating income or loss2024-10-012025-09-30-15,844,115USD2025-12-16
Current assetsAt date2025-09-3014,342,726USD2025-12-16
Interest expense2019-01-012019-12-31673,573USD2020-03-19
Current liabilitiesAt date2025-09-304,096,979USD2025-12-16
Current accounts payableAt date2025-09-302,942,331USD2025-12-16
Goodwill carrying amountAt date2019-12-318,567,888USD2020-03-19
Net finite-lived intangible assetsAt date2015-12-312,982,074USD2016-03-31
Net current accounts receivableAt date2018-12-31387,239USD2019-04-01
Operating expenses2024-10-012025-09-3016,844,115USD2025-12-16
Net inventoryAt date2019-12-31287,111USD2020-03-19
Research and development expense2024-10-012025-09-308,355,304USD2025-12-16
Common shares outstandingAt date2025-09-307,077,352shares2025-12-16
Cash including restricted cashAt date2018-12-31630,206USD2019-04-01
Additional paid-in capitalAt date2025-09-30144,479,342USD2025-12-16
Accumulated other comprehensive income or lossAt date2019-12-31-46,437USD2020-03-19
Total equity including noncontrolling interestsAt date2019-12-31-3,152,011USD2020-03-19
Operating lease right-of-use assetAt date2025-09-3043,775USD2025-12-16
Operating lease liabilityAt date2025-09-3046,573USD2025-12-16
Long-term debtAt date2019-12-316,630,961USD2020-03-19
Gross property, plant and equipmentAt date2019-12-3111,191,636USD2020-03-19
Accumulated depreciation on property, plant and equipmentAt date2019-12-315,561,146USD2020-03-19
Net intangible assets excluding goodwillAt date2019-12-313,656,995USD2020-03-19
Other noncurrent assetsAt date2025-09-30487,151USD2025-12-16
Other noncurrent liabilitiesAt date2013-12-31220,341USD2014-03-31
Accrued current liabilitiesAt date2022-09-303,193,972USD2022-12-15
Prepaid expenses and other current assetsAt date2025-09-30470,615USD2025-12-16
Net deferred tax assetsAt date2025-09-3014,658USD2025-12-16
Pre-tax income or loss from continuing operations2024-10-012025-09-30-15,793,087USD2025-12-16
Profit or loss including noncontrolling interests2019-01-012019-12-31-18,465,032USD2020-03-19
Comprehensive income or loss2019-01-012019-12-31-17,570,706USD2020-03-19
Net income available to common stockholders2024-10-012025-09-30-16,112,737USD2025-12-16
General and administrative expense2024-10-012025-09-308,488,811USD2025-12-16
Depreciation expense2024-10-012025-09-309,617USD2025-12-16
Depreciation, depletion and amortization2019-01-012019-12-311,842,352USD2020-03-19
Amortization of intangible assets2019-01-012019-12-31373,776USD2020-03-19
Nonoperating income or expense2019-01-012019-12-31-1,291,410USD2020-03-19
Interest paid, net2019-01-012019-12-31556,352USD2020-03-19
Income taxes paid, net2019-01-012019-12-31110,707USD2020-03-19
Proceeds from issuing common stock2024-10-012025-09-307,803,453USD2025-12-16
Operating lease payments2024-10-012025-09-3095,487USD2025-12-16
Change in accounts receivable2015-01-012015-12-31758,095USD2016-03-31
Change in inventories2019-01-012019-12-3168,163USD2020-03-19
Change in accounts payable2024-10-012025-09-30630,384USD2025-12-16

Filings

61 SONNET BIOTHERAPEUTICS HOLDINGS, filings with published measures: what each annual or quarterly report tagged, with the periods it covered, as reported in that filing. The histories above show the latest-filed value per period.

Inspect the source

Entity
SONNET BIOTHERAPEUTICS HOLDINGS, INC. / CIK 0001106838
Captured
2026-09-21T17:18:22.439Z
SEC response SHA-256
3f4ed3e191d870392f866d0b7de79fd0378ba4f8669f59d59de1a0b18cd3dce4

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001106838.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))